Call vs sll
Asking for Preferences
Asking for Preferences
Reading File
Finding Sources
Searching PubMed
"chronic lymphocytic leukemia" AND "small lymphocytic lymphoma"
Reading File
Reading File
Reading File
I now have excellent content from multiple authoritative textbooks. Here is the full comparison:
CLL vs SLL
The core answer: CLL and SLL are the same disease — they share identical cell biology, immunophenotype, genetics, and treatment. The distinction is purely based on where the tumor cells predominate at presentation.
The Defining Difference
| Feature | CLL | SLL |
|---|---|---|
| Definition | Peripheral blood B-lymphocytes > 5,000/µL | Peripheral blood B-lymphocytes < 5,000/µL |
| Primary site | Blood & bone marrow predominant | Lymph node predominant |
| % of NHLs | Most common adult leukemia in Western world | ~4% of NHLs |
| Diagnosis | Blood count + flow cytometry | Lymph node biopsy typically needed |
The 5,000/µL lymphocyte threshold is explicitly acknowledged as "somewhat arbitrary" — Robbins & Kumar Basic Pathology.
What They Share (Everything Else)
Cell of Origin & Immunophenotype
Both are clonal CD5+ B-cell neoplasms with the same characteristic phenotype:
- Positive: CD19, CD20, CD79a, CD5 (co-expression is key!), CD23, CD200, LEF1
- Negative: CD10, BCL-6, cyclin D1
- Dim surface immunoglobulin (IgM or IgM+IgD)
- This CD5+/CD23+ profile distinguishes CLL/SLL from mantle cell lymphoma (CD5+/CD23−) and other small B-cell lymphomas
Morphology
- Small resting lymphocytes with clumped chromatin and scant cytoplasm
- Proliferation centers (pseudofollicles): ill-defined foci of larger, actively dividing prolymphocytes — pathognomonic for CLL/SLL
- Very low mitotic rate
Pathogenesis
- BCL2 overexpression → inhibits apoptosis (tumor survival > proliferation)
- BCL2 upregulation driven partly by deletion of chr 13q14 (loss of miR-15a/16-1, which normally suppress BCL2)
- BTK (Bruton tyrosine kinase) signaling via the B-cell receptor is critical — the basis for ibrutinib and next-generation BTK inhibitor therapy
Cytogenetics (same in both)
| Abnormality | Frequency | Prognosis |
|---|---|---|
| del(13q14.3) | ~50% | Favorable |
| Trisomy 12 | ~20% | Intermediate |
| del(11q22-23) — ATM | ~20% | Adverse |
| del(17p13) — TP53 | ~10% | Adverse (BTKi preferred) |
| del(6q21) | ~5% | Adverse |
Molecular Prognostics
- Mutated IGHV (~50–60% of cases): memory B-cell-like profile → better prognosis
- Unmutated IGHV: naïve B-cell-like → worse prognosis, associated with ZAP-70 expression, NOTCH1 mutation
- SF3B1, BIRC3 mutations: additional adverse prognostic markers
Immune Dysregulation (both)
- Hypogammaglobulinemia → susceptibility to infections
- ~15% develop warm autoantibodies → autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia (ITP) — made by bystander non-malignant B cells
Clinical Spectrum & Related Entity
| Entity | B-cell count | Features |
|---|---|---|
| Monoclonal B-cell lymphocytosis (MBL) | < 5,000/µL, no cytopenias/LAD/splenomegaly | Precursor state; ~1–2%/year risk of progression to CLL requiring therapy |
| SLL | < 5,000/µL + lymphadenopathy | Same disease as CLL |
| CLL | > 5,000/µL | Same disease as SLL |
Essentially all CLL patients have a preceding MBL phase.
Treatment
Because CLL and SLL are the same entity, treatment is identical. Current first-line options per recent literature include:
- BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) — especially for del(17p)/TP53-mutated or unmutated IGHV
- BCL2 inhibitor (venetoclax) ± anti-CD20 antibody (obinutuzumab/rituximab)
- Chemoimmunotherapy (FCR) still used in fit, mutated-IGHV patients without high-risk genetics
A 2025 network meta-analysis (Liu et al., Ann Hematol 2025) compared safety profiles of first-line CLL/SLL treatments, and a 2024 systematic review (Yin et al., Ann Hematol 2024) confirmed efficacy of next-generation BTKi across CLL/SLL.
Bottom line: The CLL vs SLL distinction is a clinical staging convenience, not a biological one. Both are diagnosed, staged (Rai/Binet for CLL; Ann Arbor for SLL), and treated identically. — Goldman-Cecil Medicine, Robbins & Kumar Basic Pathology, Henry's Clinical Diagnosis
Idelisab
Finding Sources
Searching the Web
idelalisib mechanism CLL indications toxicity
Reading File
Idelalisib (Zydelig)
Drug Class & Target
Idelalisib is an oral PI3Kδ (PI3K-delta) inhibitor — the first in its class approved for B-cell malignancies.
- IC50 ~19 nM for PI3Kδ
- Selectivity: 6× over PI3Kγ; >200× over PI3Kα and PI3Kβ
- PI3Kδ is highly expressed in normal and malignant B cells
Mechanism of Action
PI3Kδ sits downstream of the B-cell receptor (BCR) and chemokine receptors (CXCR4, CXCR5) that govern B-cell trafficking and homing to lymph nodes and bone marrow. By blocking PI3Kδ, idelalisib:
- Inhibits BCR signaling (same pathway as ibrutinib/BTK, but one step further downstream at a different node)
- Blocks chemotaxis and adhesion of malignant B cells → mobilizes tumor cells out of protective niches (lymph nodes/marrow) into blood
- Induces apoptosis (caspase-dependent) and inhibits proliferation of malignant B cells
Approved Indications
For relapsed/refractory B-cell malignancies (≥2 prior therapies):
| Indication | Combination |
|---|---|
| CLL | + rituximab |
| Follicular lymphoma (FL) | Monotherapy |
| SLL | Monotherapy |
Not approved for first-line use. Notably, front-line studies were halted due to excess hepatotoxicity, especially in younger patients with mutated IGHV.
Pharmacokinetics (ADME)
| Parameter | Detail |
|---|---|
| Route | Oral; food does not affect absorption |
| Metabolism | Aldehyde oxidase, CYP3A, UGT1A4 |
| t½ | ~8.2 hours |
| Inhibits | CYP3A (↑ levels of CYP3A substrates e.g. midazolam) |
| Substrate of | P-glycoprotein (Pgp), BCRP/ABCG2 |
| Hepatic impairment | ↑ systemic exposure → ↑ toxicity risk |
Key drug interaction: Strong CYP3A inhibitors increase idelalisib toxicity. Strong CYP3A inducers reduce efficacy.
Adverse Effects
Idelalisib has a significant toxicity profile — several effects can be fatal:
| Toxicity | Frequency | Notes |
|---|---|---|
| Hepatotoxicity | 16–18% | Avoid co-administration with other hepatotoxic drugs |
| Diarrhea / Colitis (fatal) | 14–20% | Immune-mediated; requires dose interruption or steroids |
| Serious infections | 21–48% | Includes PCP, CMV, fungal; prophylaxis recommended |
| Pneumonitis | ~4% | Can be fatal |
| Fever, chills, fatigue | Common | |
| Rash | Common | |
| Hyperglycemia | Common | |
| ↑ triglycerides, ↑ LFTs | Common |
Contraindicated: Breastfeeding (embryofetal toxicity; potential harm to nursing infants).
Context in CLL Treatment
Idelalisib + rituximab is a NCCN category 2A second-line option for relapsed CLL, particularly useful in patients where BTK inhibitors are not suitable. However, its toxicity profile (especially colitis and infections) has made BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and venetoclax-based regimens the preferred choices in most settings.
Summary mnemonic: Idelalisib → "I" for PI3K-δ (the isoform), "I" for Immune-mediated toxicities (colitis, hepatitis, pneumonitis), only for relapsed disease.
— Goodman & Gilman's Pharmacological Basis of Therapeutics
This is a shared conversation. Sign in to Orris to start your own chat.